Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2015

View Archived Issues

Edge Therapeutics reports data from phase I/II of EG-1962

Alzheimer's Drug Discovery Foundation joins up with Pfizer's Centers for Therapeutic Innovation

Advaxis and Incyte to evaluate combination of two novel cancer immunotherapies

Voyager Therapeutics and Genzyme to develop novel AAV gene therapies for CNS disorders

First clinical study of Niagen meets primary endpoint

ViveBio signs licensing agreement with Renovar for urine-based biomarkers for kidney disease

Plant-produced decoy shows potential against MERS-CoV

First vaccine that shows efficacy against CCHF virus in mice

Taisho Pharmaceutical divulges GlyT-1 inhibitors

Novo Nordkisk reports development of anti-uPA MAbs

Bayer Schering Pharma discloses GnRH receptor antagonists

Roche and Genentech patent describes new PAK 1 inhibitors

The University of Colorado discloses new organosilicon anticancer agents

Affinivax collaborates with PATH to advance vaccine candidate for Pneumococcal disease

Alzheimer's Association, Weston Brain Institute and Alzheimer's Research UK join forces

First clinical study of ONS-3010 meets primary endpoints

Compugen presents data supporting potential of CGEN-15049 as target for cancer immunotherapy

Janssen launches three new research platforms

MonoSol Rx presents pipeline update

Amyloid light-chain amyloidosis treatments receive FDA orphan drug status

FDA grants orphan drug status to VS-5584 for malignant mesothelioma

IOmet Pharma discloses preclinical results for tryptophan metabolism modulators for cancer

Phase I study reveals promise of ACE-910 in hemophilia

Health Canada updates Zelboraf labeling to advise of pancreatitis risk

Repurposed maprotiline shows antibiofilm activity against Francisella

Novo Nordisk and Merck & Co. join GPCR Consortium

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...